Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received an average rating of “Moderate Buy” from the twenty-one research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $125.21.
NBIX has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on shares of Neurocrine Biosciences in a research note on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Royal Bank of Canada boosted their target price on shares of Neurocrine Biosciences from $108.00 to $110.00 in a research note on Monday, April 24th. Canaccord Genuity Group raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $124.00 to $132.00 in a research note on Thursday, March 30th. TheStreet cut shares of Neurocrine Biosciences from a “b” rating to a “c” rating in a research note on Monday, May 8th. Finally, UBS Group decreased their target price on shares of Neurocrine Biosciences from $137.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 4th.
Insider Activity at Neurocrine Biosciences
In other news, Director William H. Rastetter sold 6,034 shares of the stock in a transaction dated Friday, April 21st. The shares were sold at an average price of $105.04, for a total transaction of $633,811.36. Following the transaction, the director now owns 39,460 shares of the company’s stock, valued at approximately $4,144,878.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director William H. Rastetter sold 903 shares of the firm’s stock in a transaction dated Wednesday, April 19th. The shares were sold at an average price of $105.00, for a total value of $94,815.00. Following the transaction, the director now owns 34,729 shares of the company’s stock, valued at approximately $3,646,545. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William H. Rastetter sold 6,034 shares of the firm’s stock in a transaction dated Friday, April 21st. The shares were sold at an average price of $105.04, for a total transaction of $633,811.36. Following the completion of the transaction, the director now directly owns 39,460 shares in the company, valued at approximately $4,144,878.40. The disclosure for this sale can be found here. Insiders have sold a total of 37,034 shares of company stock worth $3,838,922 over the last quarter. Company insiders own 4.40% of the company’s stock.
Institutional Investors Weigh In On Neurocrine Biosciences
Neurocrine Biosciences Stock Performance
Shares of NASDAQ:NBIX opened at $92.18 on Friday. The company’s 50 day simple moving average is $99.30 and its 200 day simple moving average is $107.66. The stock has a market capitalization of $8.99 billion, a price-to-earnings ratio of 153.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.74. Neurocrine Biosciences has a 1 year low of $88.23 and a 1 year high of $129.29.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on Neurocrine Biosciences (NBIX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.